JP2016505003A5 - - Google Patents

Download PDF

Info

Publication number
JP2016505003A5
JP2016505003A5 JP2015549902A JP2015549902A JP2016505003A5 JP 2016505003 A5 JP2016505003 A5 JP 2016505003A5 JP 2015549902 A JP2015549902 A JP 2015549902A JP 2015549902 A JP2015549902 A JP 2015549902A JP 2016505003 A5 JP2016505003 A5 JP 2016505003A5
Authority
JP
Japan
Prior art keywords
cancer
biological sample
mammalian
binding
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015549902A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016505003A (ja
JP6286445B2 (ja
Filing date
Publication date
Priority claimed from AU2013203806A external-priority patent/AU2013203806B2/en
Application filed filed Critical
Priority claimed from PCT/AU2013/001523 external-priority patent/WO2014100857A1/en
Publication of JP2016505003A publication Critical patent/JP2016505003A/ja
Publication of JP2016505003A5 publication Critical patent/JP2016505003A5/ja
Application granted granted Critical
Publication of JP6286445B2 publication Critical patent/JP6286445B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015549902A 2012-12-24 2013-12-24 がんの治療のためのワクチン及びワクチン有効性を増強するための組成物 Expired - Fee Related JP6286445B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
AU2012905669A AU2012905669A0 (en) 2012-12-24 Vaccine booster
AU2012905667 2012-12-24
AU2012905667A AU2012905667A0 (en) 2012-12-24 Vaccines for treatment of cancer
AU2012905669 2012-12-24
AU2013203806A AU2013203806B2 (en) 2012-12-24 2013-04-11 Vaccines for the treatment or prevention of cancer
AU2013203806 2013-04-11
AU2013903592 2013-09-18
AU2013903592A AU2013903592A0 (en) 2013-09-18 Vaccines for the treatment or prevention of cancer
PCT/AU2013/001523 WO2014100857A1 (en) 2012-12-24 2013-12-24 Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018017162A Division JP2018111695A (ja) 2012-12-24 2018-02-02 がんの治療のためのワクチン及びワクチン有効性を増強するための組成物

Publications (3)

Publication Number Publication Date
JP2016505003A JP2016505003A (ja) 2016-02-18
JP2016505003A5 true JP2016505003A5 (enExample) 2017-02-09
JP6286445B2 JP6286445B2 (ja) 2018-02-28

Family

ID=53547734

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015549902A Expired - Fee Related JP6286445B2 (ja) 2012-12-24 2013-12-24 がんの治療のためのワクチン及びワクチン有効性を増強するための組成物
JP2018017162A Pending JP2018111695A (ja) 2012-12-24 2018-02-02 がんの治療のためのワクチン及びワクチン有効性を増強するための組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018017162A Pending JP2018111695A (ja) 2012-12-24 2018-02-02 がんの治療のためのワクチン及びワクチン有効性を増強するための組成物

Country Status (7)

Country Link
US (2) US10357538B2 (enExample)
EP (2) EP3446708A1 (enExample)
JP (2) JP6286445B2 (enExample)
AU (1) AU2013370932B2 (enExample)
CA (1) CA2934958A1 (enExample)
NZ (1) NZ629700A (enExample)
WO (1) WO2014100857A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3446708A1 (en) * 2012-12-24 2019-02-27 Cell Ideas Pty Ltd. Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
SG11201806587RA (en) 2016-02-04 2018-09-27 Longeveron Llc Mesenchymal stem cells as vaccine adjuvants and methods for using the same
JP6971986B2 (ja) * 2016-04-01 2021-11-24 アプセト ゲーエムベーハー アンド ツェーオー．カーゲー 免疫療法の抗腫瘍活性を高めるための間葉系幹細胞
US11054389B2 (en) * 2018-03-19 2021-07-06 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62221636A (ja) * 1986-03-20 1987-09-29 Chemo Sero Therapeut Res Inst Ｂ型肝炎ウイルス抗原蛋白の可溶化方法
US5030621A (en) * 1987-04-23 1991-07-09 Bystryn Jean Claude Shed melanoma antigen compositions
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6379671B1 (en) * 1996-08-19 2002-04-30 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
CA2302339A1 (en) 1997-09-20 1999-04-01 Osiris Therapeutics, Inc. Antigen presenting mesenchymal stem cells
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US7229960B2 (en) * 2000-11-03 2007-06-12 University Of Vermont And State Agricultural College Methods and compositions for inhibiting GRB7
US20040076622A1 (en) * 2002-03-02 2004-04-22 Board Of Regents, The University Of Texas System Local production and/or delivery of anti-cancer agents by stromal cell precursors
AU2004268497A1 (en) * 2003-02-28 2005-03-10 Antigenics Inc. Use of lectins to promote oligomerization of glycoproteins and antigenic molecules
AU2003903317A0 (en) 2003-06-27 2003-07-10 Proteome Systems Intellectual Property Pty Ltd Method of isolating a protein
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
CA2564679C (en) 2004-03-22 2015-06-23 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
KR101022401B1 (ko) * 2005-09-29 2011-03-15 아주대학교산학협력단 자살유전자를 발현하는 중간엽 줄기세포를 포함하는 암치료용 조성물
CN1887296B (zh) * 2006-07-31 2011-05-25 南京大学生物制药工程研究中心 一种诱导抗肿瘤免疫的方法及其在制药中的应用
US8685728B2 (en) * 2008-01-31 2014-04-01 Rutgers The State University Of New Jersey Kit containing stem cells and cytokines for use in attenuating immune responses
US8771705B2 (en) 2009-07-30 2014-07-08 Healthbanks Biotech Co., Ltd. Combination of protein vaccine and mesenchymal stem cells for treating cancer
KR20110038569A (ko) * 2009-10-08 2011-04-14 주식회사 알앤엘바이오 인간 유래 성체 줄기세포를 함유하는 항암용 조성물
JP2013510582A (ja) * 2009-11-12 2013-03-28 ザ テキサス エーアンドエム ユニバーシティー システム 間葉幹細胞の球状集合体
KR20120132183A (ko) * 2011-05-27 2012-12-05 포항공과대학교 산학협력단 종양 조직에서 유래한 나노소포체 및 이를 이용한 암 백신
SG10201606745XA (en) 2011-09-23 2016-10-28 Cell Ideas Pty Ltd Therapeutics using adipose cells and cell secretions
EP3446708A1 (en) * 2012-12-24 2019-02-27 Cell Ideas Pty Ltd. Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy

Similar Documents

Publication Publication Date Title
Jeon et al. Side-effect test of sorafenib using 3-D skin equivalent based on microfluidic skin-on-a-chip
Darbre Aluminium and the human breast
Ito et al. Contrasting intra-and extracellular distribution of catalytic ferrous iron in ovalbumin-induced peritonitis
Olsen et al. Manipulation of cellular spheroid composition and the effects on vascular tissue fusion
Del Turco et al. Cytocompatibility evaluation of glycol-chitosan coated boron nitride nanotubes in human endothelial cells
Xu et al. Glycogen synthase kinase 3β dictates podocyte motility and focal adhesion turnover by modulating paxillin activity: implications for the protective effect of low-dose lithium in podocytopathy
Klein Evolutionary aspects of cancer resistance
Thakur et al. Expression and localization of heat-shock proteins during skeletal muscle cell proliferation and differentiation and the impact of heat stress
Chen et al. Invisible bridges: unveiling the role and prospects of tunneling nanotubes in cancer therapy
Wu et al. A selective reduction of osteosarcoma by mitochondrial apoptosis using hydroxyapatite nanoparticles
Xie et al. Mechanically stimulated osteocytes maintain tumor dormancy in bone metastasis of non-small cell lung cancer by releasing small extracellular vesicles
Reding et al. Manipulate intestinal organoids with niobium carbide nanosheets
Nightingale et al. The migrating gubernaculum grows like a “limb bud”
Roy et al. Attenuation of cadmium-induced vascular toxicity by pro-angiogenic nanorods
Kucki et al. Impact of graphene oxide on human placental trophoblast viability, functionality and barrier integrity
Gommers et al. Development of a villi-like micropatterned porous membrane for intestinal magnesium and calcium uptake studies
Gong et al. Implant derived high local concentration of magnesium inhibits tumorigenicity of osteosarcoma
Hussein et al. Induction of caspase-dependent apoptosis in rat bone marrow mesenchymal stem cells due to di-2-ethylhexyl phthalate toxicity was found to arrest the cell cycle at the G1 stage
Su et al. Novel in situ biosynthesized fluorescent zinc nanoclusters for specific cellular bio-imaging
Degrelle et al. Iodide transporters expression in early human invasive trophoblast
Altundag et al. The role of HSP90 in Quercetin-induced apoptosis in human papillary thyroid (B-CPAP) cancer cells
Čunderlíková Clinical significance of immunohistochemically detected extracellular matrix proteins and their spatial distribution in primary cancer
Selc et al. Surface coating determines the inflammatory potential of magnetite nanoparticles in murine renal podocytes and mesangial cells
Raza et al. CD73 and cN-II regulate the cellular response to chemotherapeutic and hypoxic stress in lung adenocarcinoma cells
Bhardwaj et al. Co-delivery of JQ1 and Gambogic acid through tumor-targeting PEGylated nanographene oxide with FSH beta peptide (33–53) identifies SNHG7-hsa-miR-324-3p-SMAD2 axis as a prognostic biomarker in ovarian cancer